VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection
SAN DIEGO RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,&rdq
Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff.
“@sanjiv_chopra
➡️Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff. Work in progress on alcoholism, autism, and others.
➡️AI will shape how we practice. EKG can predict cirrhosis
➡️CRISPR will shape the future of the human race
@DDWMeeting #DDW2022”
Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting - Business Wire
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes
Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes pic.twitter.com/mc7hGS0wLB— Mindy Engevik (@MicroMindy) May 21, 2022
Thomas Louie is showing beautiful work using 8 bacterial strains to prevent the recurrence of #Cdiff #DDW2022 #microbes
Thomas Louie is showing beautiful work using 8 bacterial strains to prevent the recurrence of #Cdiff #DDW2022 #microbes pic.twitter.com/NOt5GtrsVI— Mindy Engevik (@MicroMindy) May 21, 2022
Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection
The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein …
Recent development of small-molecular inhibitors against Clostridioides difficile infection
Clostridioides difficile infection is one of the leading causes of antibiotic-associated infectious diarrhea, and is associated with increased incidence and severity worldwide. While antibiotics have traditionally been used for prophylaxis and treatment of C. difficile infection, elevated antibiotic …
Human α-Defensin-6 Neutralizes Clostridioides difficile Toxins TcdA and TcdB by Direct Binding
Rising incidences and mortalities have drawn attention to Clostridioides difficile infections (CDIs) in recent years. The main virulence factors of this bacterium are the exotoxins TcdA and TcdB, which glucosylate Rho-GTPases and thereby inhibit Rho/actin-mediated processes in cells. This res …
12 May 2022 – Landmark NTCD-M3 data to be presented at Anaerobe | Destiny Pharma
Destiny Pharma plc ("Destiny Pharma" or "the Company") World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration Brighton, United Kingdom – 12 May 2022 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting - GuruFocus.com
GuruFocus Article or News written by Business Wire and the topic is about:
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022 - Business Wire
Novel Antibiotic Shows Promise for C diff Infection - Medscape
A novel antibiotic therapy for Clostridioides difficile infection, currently dubbed CRS3123, has demonstrated narrower selectivity and reduced bacterial derangement in the gut compared with other antibiotics.
C. diff to be treated with 'bacteria-eating viruses' - Medical News Today
Researchers have found that viruses called 'bacteriophages' are able to destroy the problematic Clostridium difficile bacterium and could lead to new treatment methods.
In Vitro and In Silico Based Approaches to Identify Potential Novel Bacteriocins from the Athlete Gut Microbiome of an Elite Athlete Cohort - PubMed
Exercise reduces inflammation, fatigue, and aids overall health. Additionally, physical fitness has been associated with desirable changes in the community composition of the athlete gut microbiome, with health-associated taxa being shown to be increased in active individuals. Here, using a combinat …
Lactiplantibacillus plantarum E51 protects against Clostridioides difficile-induced damages on Caco-2 intestinal barrier functions - PubMed
Clostridioides difficile (C. difficile) infection is associated with high morbidity and mortality. This study aimed to evaluate the protective effect of Lactiplantibacillus plantarum E51 (L. plantarum E51) on C. difficile infection using the Caco-2 monolayer in vitro model. Caco-2 cells were infecte …
U.S. FDA removes Clinical Hold on Finch’s investigational new drug (IND) application for CP101 - Benzinga - Benzinga
The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in the prevention of recurrent C. difficile infection (CDI).
Adiso Therapeutics Announces Completion of Enrollment in a Phase 1b Study of ADS024 for the Prevention of C. difficile Recurrence
Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product (SS-LBP), for the prevention of C. difficile infection (CDI) recurrence.
Clostridium difficile infection after ileostomy closure and anastomotic failure in rectal cancer surgery patients
Adjuvant chemotherapy and colorectal anastomosis leakage increase risk of Clostridium difficile infection. Patients with Clostridium difficile infection also ha
Finch Slashes 20% of Headcount to Hone in on C.Diff, Autism
Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder